Literature DB >> 12899708

Flt3 mutations and leukaemia.

Panagiotis D Kottaridis1, Rosemary E Gale, David C Linch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12899708     DOI： 10.1046/j.1365-2141.2003.04500.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  29 in total

1.  NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.

Authors:  Patricia Rubio; B Campos; J A Digiorge; M S Gallego; A Medina; J G Rossi; M S Felice; C N Alonso
Journal:  Int J Hematol       Date:  2016-07-19       Impact factor: 2.490

Review 2.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 3.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

4.  The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.

Authors:  Ewa Augustin; Anna Skwarska; Anna Weryszko; Iwona Pelikant; Ewa Sankowska; Barbara Borowa-Mazgaj
Journal:  Acta Pharmacol Sin       Date:  2015-02-02       Impact factor: 6.150

5.  Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.

Authors:  Talha Badar; Hagop M Kantarjian; Graciela M Nogueras-Gonzalez; Gautam Borthakur; Guillermo Garcia Manero; Michael Andreeff; Marina Konopleva; Tapan M Kadia; Naval Daver; William G Wierda; Raja Luthra; Keyur Patel; Betul Oran; Richard Champlin; Farhad Ravandi; Jorge E Cortes
Journal:  Am J Hematol       Date:  2015-09-10       Impact factor: 10.047

6.  Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.

Authors:  Rehan Ahmad; Suiyang Liu; Ellen Weisberg; Erik Nelson; Ilene Galinsky; Colin Meyer; Donald Kufe; Surender Kharbanda; Richard Stone
Journal:  Mol Cancer Res       Date:  2010-06-22       Impact factor: 5.852

7.  Up-regulation of homeodomain genes, DLX1 and DLX2, by FLT3 signaling.

Authors:  Julia Starkova; Sharvari Gadgil; Yi Hua Qiu; Nianxiang Zhang; Ivana Hermanova; Steven M Kornblau; Harry A Drabkin
Journal:  Haematologica       Date:  2011-02-28       Impact factor: 9.941

8.  Development and Characterization of FLT3-Specific Curcumin-Loaded Polymeric Micelles as a Drug Delivery System for Treating FLT3-Overexpressing Leukemic Cells.

Authors:  Singkome Tima; Siriporn Okonogi; Chadarat Ampasavate; Chad Pickens; Cory Berkland; Songyot Anuchapreeda
Journal:  J Pharm Sci       Date:  2016-10-14       Impact factor: 3.534

9.  Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.

Authors:  Alison R Walker; Rebecca Klisovic; Jeffrey S Johnston; Yao Jiang; Susan Geyer; Cheryl Kefauver; Philip Binkley; John C Byrd; Michael R Grever; Ramiro Garzon; Mitch A Phelps; Guido Marcucci; Kristie A Blum; William Blum
Journal:  Leuk Lymphoma       Date:  2013-01-24

10.  Applications of microarray technology to Acute Myelogenous Leukemia.

Authors:  Rashmi S Goswami; Mahadeo A Sukhai; Mariam Thomas; Patricia P Reis; Suzanne Kamel-Reid
Journal:  Cancer Inform       Date:  2008-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.